COPENHAGEN — Relative to starting on an immunomodulator and then switching to a more potent anti-CD20 monoclonal antibody, the likelihood of long-term accumulation of disability in […]

COPENHAGEN, Denmark — A higher cumulative genetic burden for depression is associated with an increased risk for relapse and worsening disability in people with multiple sclerosis […]

(Reuters) -The U.S. Food and Drug Administration approved IntraBio’s drug for a rare and fatal genetic disorder, the health regulator said on Tuesday, just days after […]

COPENHAGEN — In two phase 3 head-to-head comparing the Bruton tyrosine kinase inhibitor (BTKi) tolebrutinib to the immunomodulatory teriflunomide for relapsing-remitting multiple sclerosis (RRMS), there was […]

COPENHAGEN — The largest and perhaps most rigorous study to demonstrate an association between the presence of comorbidities and accelerated progression of multiple sclerosis (MS) is […]

COPENHAGEN — As a rescue intervention for multiple sclerosis (MS), hematopoietic stem cell transplant (HSCT) is being offered with greater frequency at centers experienced with this […]

COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). The Phase […]

Air pollution, high temperatures, and metabolic risk factors are driving global increases in stroke, contributing to 12 million cases and more than 7 million deaths from […]

A series of neutral trials on anticoagulation in embolic stroke of undetermined source (ESUS) has moved the needle scientifically but left physicians with questions about secondary […]